Big Pharma is set to increase acquisitions in 2025 due to patent expirations on top-selling drugs like Keytruda and Eliquis. Focus areas for acquisitions include obesity, oncology, immunology, and cardiovascular drugs, aiming to fill revenue gaps and capitalize on emerging markets.